EMPOWER-Lung 1: Phase III first-line (1L) cemiplimab monotherapy vs platinum-doublet chemotherapy (chemo) in advanced non-small cell lung cancer (NSCLC) with programmed cell death-ligand 1 (PD-L1) >= 50%

Author
Gogishvili, M.
Sezer, A.
Kilickap, S.
Gumus, M.
Bondarenko, I.
ÖZGÜROĞLU, Mustafa
TÜRK, HACI MEHMET
Cicin, I.
Bentsion, D.
Gladkov, O.
Clingan, P.
Sriuranpong, V.
Rizvi, N.
Li, S.
Lee, S.
Gullo, G.
Lowy, I.
Rietschel, P.
Metadata
Show full item record
URI
http://hdl.handle.net/20.500.12627/18097
https://doi.org/10.1016/j.annonc.2020.08.2285
Collections